Id: CBI_1976 | Pages: 224 | Format : PDF | Published : | Author : Amit Sati | Category : Pharmaceuticals
Gene Panel Market size is estimated to reach over USD 13,114.95 Million by 2032 from a value of USD 3,560.85 Million in 2024 and is projected to grow by USD 4,127.67 Million in 2025, growing at a CAGR of 17.7% from 2025 to 2032.
Gene panels are diagnostic tools designed to analyze multiple genes simultaneously for identifying genetic mutations linked to diseases or traits. These panels utilize advanced sequencing technologies to provide accurate and reliable results in a time-efficient manner. Gene panels offer features like high specificity, targeted sequencing, and customizable content for disease-specific gene analysis. They support precision medicine by identifying genetic predispositions and facilitating tailored treatment plans.
The benefits of gene panels include efficient diagnosis, cost-effectiveness, and reduced testing time. They enhance healthcare outcomes by enabling early detection of hereditary conditions and complex disorders. Applications of gene panels span oncology, cardiology, neurology, and rare genetic diseases. End-use industries include clinical diagnostics, research institutions, biotechnology firms, and pharmaceutical companies, underscoring their significance in advancing medical research and patient care.
Gene panels are widely adopted for identifying genetic mutations associated with various cancers, aiding in precise diagnosis and personalized treatment plans. These panels enable healthcare professionals to detect actionable mutations by analyzing multiple genes simultaneously, streamlining the diagnostic process and improving patient outcomes. For instance, BRCA1 and BRCA2 gene panels are used to identify breast and ovarian cancer risks, facilitating timely medical intervention.
This critical role of gene panels in enhancing cancer diagnostics significantly contributes to the gene panel market expansion.
The expenses associated with gene panel testing, including laboratory infrastructure, reagents, and professional expertise, restrict adoption, particularly in low-income regions. These costs create financial barriers for patients and healthcare systems, impacting widespread utilization. For example, comprehensive gene panels for hereditary diseases can cost thousands of dollars, limiting accessibility for many patients.
The high costs involved in gene panel testing hinder market adoption, particularly among economically constrained populations.
The integration of artificial intelligence (AI) into gene panel testing is anticipated to transform the market by enhancing data analysis and interpretation accuracy. AI algorithms will facilitate faster identification of genetic variants, improving the reliability of test results and accelerating clinical decision-making processes. For instance, AI-driven platforms are expected to identify rare mutations more efficiently, enabling early disease detection and prevention strategies.
The future application of AI-powered analytics in gene panel testing is poised to unlock substantial gene panel market opportunities, driving innovation and adoption globally.
Based on product and service, the gene panel market is segmented into test kits & reagents and services.
The test kits & reagents segment accounted for the largest revenue in gene panel market share in 2023.
The services sector is anticipated to register the fastest CAGR during the forecast period.
Based on technique, the market is segmented into amplicon-based targeted sequencing and hybridization-based targeted sequencing.
The amplicon-based targeted sequencing segment accounted for the largest revenue in gene panel market share in 2023.
The hybridization-based targeted sequencing segment is anticipated to register the fastest CAGR during the forecast period.
Based on design, the market is segmented into predesigned gene panels and customized gene panels.
The predesigned gene panels segment accounted for the largest revenue share in 2023.
The customized gene panels segment is expected to register the fastest CAGR during the forecast period.
Based on application, the gene panel market is segmented into cancer risk assessment, pharmacogenetics, diagnosis of congenital disorders, and others.
The cancer risk assessment segment accounted for the largest revenue share of 46.50% in 2023.
The pharmacogenetics segment is anticipated to register the fastest CAGR during the forecast period.
Based on end-users, the gene panel market is segmented into hospitals & diagnostic laboratories, academic & research institutions, and pharmaceutical & biotechnology companies.
The hospitals & diagnostic laboratories segment accounted for the largest revenue share in 2023.
The pharmaceutical & biotechnology companies segment is anticipated to register the fastest CAGR during the forecast period.
The regional segment includes North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
In 2024, North America was valued at USD 1,181.16 Million and is expected to reach USD 4,250.56 Million in 2032. In North America, the U.S. accounted for the highest share of 74.10% during the base year of 2024. The United States leads the market due to strong investments in healthcare and biotechnology. The adoption of advanced genetic testing technologies, particularly for cancer and hereditary diseases, supports the demand for gene panels. Additionally, the presence of well-established healthcare infrastructure and key players in the region, along with increased awareness of personalized medicine, accelerates gene panel market trend. Moreover, research funding and advancements in genomics further enhance market performance in North America.
In Asia Pacific, the market is experiencing the fastest growth with a CAGR of 18.2% over the forecast period. It is driven by growing healthcare needs and the increasing prevalence of genetic disorders. Countries like China, Japan, and India are focusing on improving healthcare services, leading to higher demand for genetic testing solutions. The region's rising investments in biotechnology and genomics research contribute to the adoption of gene panels. Furthermore, the growing focus on personalized medicine and precision healthcare in emerging markets like India and China significantly boosts market performance.
Europe represents a significant portion of the global gene panel market, with countries like Germany, the UK, and France contributing the most. The demand for gene panels is primarily driven by the increasing prevalence of genetic diseases and the growing use of genetic testing in clinical applications. Europe’s strong regulatory framework, which supports personalized medicine and genomic research, further enhances market adoption. The region’s public healthcare systems are increasingly integrating genetic testing into routine clinical practice, expanding the application of gene panels across various therapeutic areas, including oncology and rare genetic disorders.
The Middle East and Africa exhibit moderate gene panel market trend. While the region's healthcare infrastructure continues to develop, the adoption of gene panels remains limited by factors such as economic constraints and access to advanced healthcare technologies. However, countries like the UAE and Saudi Arabia are making significant progress in expanding their healthcare systems, which supports the demand for genetic testing services. Increased awareness of genetic diseases and growing investment in healthcare technologies contribute to a gradual rise in the use of gene panels across the region.
Latin America presents a growing but relatively untapped market for gene panels. Brazil and Mexico are the leading markets in the region, with rising awareness of genetic testing and personalized medicine. However, challenges such as limited healthcare infrastructure and economic constraints hinder the widespread adoption of gene panels. Despite these challenges, the region's growing focus on improving healthcare access and the rising prevalence of genetic disorders, including cancer and inherited diseases, offer opportunities for the gene panel market. Additionally, collaborations with global healthcare organizations and advancements in genomics research are expected to drive market development in Latin America.
The Global Gene Panel Market is highly competitive with major players providing FWA to the national and international markets. Key players are adopting several strategies in research and development (R&D), product innovation, and end-user launches to hold a strong position in the Global Gene Panel Market. Key players in the Gene Panel industry include-
Report Attributes | Report Details |
Study Timeline | 2019-2032 |
Market Size in 2032 | USD 13,114.95 million |
CAGR (2025-2032) | 17.7% |
By Product Type |
|
By Technique |
|
By Design |
|
By Application |
|
By End-User |
|
By Region |
|
Key Players |
|
North America | U.S. Canada Mexico |
Europe | U.K. Germany France Spain Italy Russia Benelux Rest of Europe |
APAC | China South Korea Japan India Australia ASEAN Rest of Asia-Pacific |
Middle East and Africa | GCC Turkey South Africa Rest of MEA |
LATAM | Brazil Argentina Chile Rest of LATAM |
Report Coverage |
|
In 2024, the Gene Panel Market was USD 3,560.85 million.
In 2032, the market size of Gene Panel Market is expected to reach USD 13,114.95 million.
The product type, technique, design, application, and end-user are the segments covered in this report.
Thermo Fisher Scientific Inc. (United States), Illumina, Inc. (United States), Agilent Technologies Inc. (United States), QIAGEN N.V. (Germany), Myriad Genetics, Inc. (United States), Foundation Medicine, Inc. (United States), Bio-Rad Laboratories, Inc. (United States), PerkinElmer Inc. (United States), Oxford Nanopore Technologies (United Kingdom), MedGenome Labs Pvt. Ltd. (India) are the major players in the Gene Panel market.